Literature DB >> 20607336

Seizure after intrathecal baclofen bolus in a multiple sclerosis patient treated with oxcarbazepine.

Giangaetano D'Aleo1, Carmela Rifici, Markus Kofler, Edoardo Sessa, Leopold Saltuari, Placido Bramanti.   

Abstract

Epileptic seizures associated with intrathecal baclofen (ITB) application have been observed in patients with traumatic brain injury. A higher incidence of seizures has also been reported in patients with multiple sclerosis (MS) receiving ITB. To our knowledge, no case of a first epileptic seizure has been reported in the context of ITB bolus testing in MS. We report a 41-year-old female patient with primary progressive MS receiving olanzapine and oxcarbazepine for psychotic disorder. Five years prior she began to develop severe spastic quadriparesis, rendering her a candidate for ITB treatment. After ITB test bolus application, however, she experienced a first epileptic seizure. Our observation indicates that ITB may trigger seizures in patients with MS. The observed seizure occurred during ITB bolus testing despite antiepileptic co-medication, which concurs with previous reports suggesting that rapid changes in the dose of ITB may carry a higher risk of seizure induction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607336     DOI: 10.1007/s10072-010-0364-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  Status epilepticus complicating intrathecal baclofen overdose.

Authors:  L Saltuari; M J Marosi; M Kofler; G Bauer
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

2.  Olanzapine-induced myoclonic status.

Authors:  Ana Camacho; Magdalena García-Navarro; Begoña Martínez; Alberto Villarejo; Eva Pomares
Journal:  Clin Neuropharmacol       Date:  2005 May-Jun       Impact factor: 1.592

3.  Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen.

Authors:  Claudio Solaro
Journal:  Neurology       Date:  2006-03-14       Impact factor: 9.910

4.  Intrathecal baclofen for cerebral spasticity.

Authors:  D Dralle; G Neuhäuser; J C Tonn
Journal:  Lancet       Date:  1989-10-14       Impact factor: 79.321

5.  Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen.

Authors:  S U Schuele; C Kellinghaus; S J Shook; N Boulis; F A Bethoux; T Loddenkemper
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Baclofen has a proepileptic effect in the rat dentate gyrus.

Authors:  D D Mott; A C Bragdon; D V Lewis; W A Wilson
Journal:  J Pharmacol Exp Ther       Date:  1989-06       Impact factor: 4.030

7.  Epileptic seizures associated with intrathecal baclofen application.

Authors:  M Kofler; M F Kronenberg; C Rifici; L Saltuari; G Bauer
Journal:  Neurology       Date:  1994-01       Impact factor: 9.910

8.  Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990-1998.

Authors:  P A Nyquist; G D Cascino; M Rodriguez
Journal:  Mayo Clin Proc       Date:  2001-10       Impact factor: 7.616

9.  Status epilepticus in a patient treated with olanzapine and mirtazapine.

Authors:  S Spyridi; S Sokolaki; J Nimatoudis; A Iacovides; G Kaprinis
Journal:  Int J Clin Pharmacol Ther       Date:  2009-02       Impact factor: 1.366

  9 in total
  1 in total

1.  Management of intrathecal baclofen therapy for severe acquired brain injury: consensus and recommendations for good clinical practice.

Authors:  Antonio De Tanti; Federico Scarponi; Michele Bertoni; Giulio Gasperini; Bernardo Lanzillo; Franco Molteni; Federico Posteraro; Dino Francesco Vitale; Mauro Zanpolini
Journal:  Neurol Sci       Date:  2017-05-06       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.